Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)
Information source: Groupe Francophone des Myelodysplasies
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Myelodysplastic Syndrome
Intervention: Azacitidine (Drug)
Phase: Phase 1/Phase 2
Status: Active, not recruiting
Sponsored by: Groupe Francophone des Myelodysplasies Official(s) and/or principal investigator(s): Lionel Adès, MD, Study Chair, Affiliation: Groupe Francophone des Myélodysplasies Simone Boehrer, MD, Principal Investigator, Affiliation: Groupe Francophone des Myélodysplasies
Summary
A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine
(Vidaza®) in intermediate-2 and high risk MDS patients.
Clinical Details
Official title: A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza®) in Intermediate-2 and High Risk MDS Patients
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Response rate (including CR and PR) according to IWG 2006 criteria for MDS after 4 and 8 cycles 75mg/m2/d azacitidine administered every 2 weeks.
Secondary outcome: Safety/toxicity profile of azacitidine administered every 14 days (NCI-CTAE)Responses (CR, PR, marrow CR, HI) according to IWG 2006 criteria and their duration. Overall survival and progression (IPSS/AML) free survival.
Detailed description:
The study is an open-label, multicenter phase I/II study.
Treatment Regimen, Dosage and Duration:
Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles
(azacitidine-14, cycles 1-4).
- Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d
for 5 days administered every 21 days (azacitidine-21, cycles 5 to 8) followed by
cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (azacitidine-28,
cycles 9 and beyond), to be continued until progression/relapse or toxicity arises).
- Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will
continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional
cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be
treated with azacitidine 75mg/m2/d for 5 days every 21 days (azacitidine-21, cycles 9
to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every
28 days (azacitidine-28, cycles 13 and beyond) until progression/relapse or toxicity
arises.
- Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go
"off-study".
Number of patients to be included:
The trial will enroll at least 27 patients (phase I of the trial) and a maximum of 81
patients (phase II of the trial). A safety analysis will be performed by an independent DSMB
after inclusion of 9, 18 and 27 patients. This safety analysis will focus particularly on
the clinical consequences of cytopenias. Moreover, a teleconference will be organized twice
monthly between the PI and investigators to share safety observations and take appropriate
actions if needed. CRFs will be collected every cycle focusing particularly on the safety of
this dose intensified study. All AE and SAE will be reported to the DSMB upon reception.
Primary Endpoint:
- Response rate (including CR and PR) according to IWG 2006 criteria for MDS after 4 and 8
cycles 75mg/m2/d azacitidine administered every 2 weeks.
Secondary Endpoints:
- Safety/toxicity profile of azacitidine administered every 14 days (NCI-CTAE)
- Responses (CR, PR, marrow CR, HI) according to IWG 2006 criteria and their duration
- Overall survival and progression (IPSS/AML) free survival.
Sample Size and Duration of Trial:
The first stage of the trial will include 27 patients. The trial will be terminated if 9 or
fewer responses are observed. Otherwise, additional patients will be recruited in the second
stage until a total sample size of 81 patients is reached.
Duration of inclusion: 24 months for 81 patients Duration of follow-up: 24 months
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- MDS defined according to WHO classification (also including RAEB-T according to FAB
classification) (see appendix 1) with intermediate-2 or high risk IPSS (see appendix
1).
- Age ≥ 18 years and <75 years.
- Must understand and voluntarily sign an informed consent form.
- Must be able to adhere to the study visit schedule and other protocol requirements.
- Patients must have ECOG performance status (PS) of 0 - 2, and no major comorbidities
preventing administration of an intensified regimen of azacitidine.
- Women of child-bearing potential (i. e., women who are pre-menopausal or not
surgically sterile) must :
- Have a negative serum or urine pregnancy test within 2 weeks prior to beginning
treatment on this study. Lactating patients are excluded.
- Agree to use, and to be able to comply with, effective contraception without
interruption, 4 weeks before starting study drug throughout the entire duration study
drug therapy (including doses interruptions) and for 3 months after the end of the
study drug therapy.
- Male patients must :
- Agree the need for the use of a condom if engaged in sexual activity with a woman of
childbearing potential during the entire period of treatment, even if disruption of
treatment and during 3 months after end of treatment.
- Agree to learn about the procedures for preservation of sperm before starting
treatment.
- Creatinine < 1. 5 N or estimated clearance of creatinine above 30 ml/min.
- Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT)
or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) < 3. 0 x
upper limit of normal (ULN).
- Serum total bilirubin < 1. 5 mg/dL. (except for unconjugated hyperbilirubinemia due to
Gilbert's disease or secondary to MDS-related dyserythropoiesis).
- Health insurance
Exclusion Criteria:
- Patients with a history of myeloproliferative syndrome or CMML.
- Known positive status for human immunodeficiency virus (HIV) or hepatitis B or C.
- Pregnant and lactating patients are excluded because the effects of azacitidine on a
fetus or a breast-fed child are unknown.
- Uncontrolled intercurrent illness including, but not limited to uncontrolled
infection, symptomatic congestive heart failure (NYHA > II), cardiac arrhythmia, or
psychiatric illness/social situations that would limit compliance with study
requirements.
- Patients receiving any other standard or investigational cytotoxic treatment for
their hematologic malignancy in the last 8 weeks
- Any medical condition which in the opinion of the investigator places the patient at
an unacceptably high risk for toxicities of an intensified regimen of azacitidine.
- Less than 6 months since prior allogeneic bone marrow transplantation.
- Less than 3 months since prior autologous bone marrow or stem cell transplantation
- Active cancer or prior history of malignancy other than MDS (except basal cell or
squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the
subject has been free of disease for ≥ 3 years.
- Prior treatment with azacitidine.
- Known allergy/intolerance to azacitidine or mannitol.
- ECOG > 2.
- Life expectancy of less than 3 months.
Locations and Contacts
CHU d'Amiens, Amiens 80054, France
Centre Hospitalier de La Cote Basque, Bayonne 64100, France
Hôpital Avicenne, Bobigny 93009, France
CHU de Haut-Lévèque, Bordeaux Pessac 33604, France
Centre henri Mondor, Creteil 94010, France
Centre Hospitalier du Mans, Le Mans cedex 72037, France
Hôpital Huriez, Lille 59037, France
Hôpital Paoli Calmettes, Marseille 13273, France
Centre Hospitalier de Meaux, Meaux 77100, France
CHU Brabois, Nancy 54511, France
CHU de nantes, Nantes 44093, France
Hôpital l'Archet de Nice, Nice 06202, France
Hopital Saint Louis - AP-HP, Hematology Dpt, Paris 75475, France
Hôpital Cochin, Paris 75004, France
Hôpital Saint Louis, Paris 75010, France
CHU de Poitiers, Poitiers 86021, France
CHRU Annecy Hospital, Pringy 74374, France
Hôpital Pontchaillou, Rennes 35033, France
Hopital Purpan Service d'Hématologie Clinique, Toulouse 31059, France
CH de Valence, Valence 26953, France
Service d'Hématologie Clinique, CHU Albert Michallon, Grenoble 38043, France
Additional Information
Website of the Groupe Francophone des Myélodysplasies (GFM)
Starting date: July 2011
Last updated: April 23, 2015
|